Introduction
============

Informed consent has its roots in the 1947 Nuremberg Code and the 1964 Declaration of Helsinki and is now a guiding principle for conduct in medical research.[@R1]^,^[@R2] Within its ethical and legal foundations,[@R3] informed consent has two specific goals in clinical research: (i) to respect and promote a participant's autonomy; and (ii) to protect participants from harm.[@R4]^,^[@R5] Obtaining written informed consent from participants before enrolment in a study is an internationally accepted standard.[@R6]^--^[@R10]

Five concepts must be considered in establishing informed consent: voluntariness, capacity, disclosure, understanding and decision.[@R11]^,^[@R12] Voluntariness means that an individual's decision to participate is made without coercion or persuasion. Capacity relates to an individual's ability to make decisions that stems from his or her ability to understand the information provided. Disclosure involves giving research participants all relevant information about the research, including its nature, purpose, risks and potential benefits as well as the alternatives available.[@R13] Understanding implies that research participants are able to comprehend the information provided and appreciate its relevance to their personal situations. Decision is that made to participate, or not.[@R11]^,^[@R12]

The quality of informed consent in clinical research is determined by the extent to which participants understand the process of informed consent.[@R14] Understanding plays a pivotal role in clinical research because it directly affects how ethical principles are applied in practice.[@R15]^--^[@R17] Although the literature on informed consent began to accumulate in the 1980s, little is known about how patients' understanding has evolved as no meta-analysis has been previously performed. A systematic review considering literature up to 2006 found that only around 50% of participants understood all components of informed consent in surgical and clinical trials.[@R18] Another systemic review, which included data up to 2010, compared only the quality of informed consent in developing and developed countries.[@R19] The objective of this study was, therefore, to investigate the quality of informed consent in clinical trials in recent decades by performing a systematic review and meta-analysis of the data available.

Methods
=======

We conducted a literature search of PubMed and Scopus using the following terms: "informed consent\[mh\] AND (comprehension\[mh\] OR decision making\[mh\] OR knowledge\[mh\] OR perception\[mh\] OR communication\[mh\] OR understanding) AND (randomized controlled trials as topic\[mh\] OR clinical trial as topic\[mh\])". In addition, in a simple search of Scopus, we used: "allintitle: understanding OR comprehension OR knowledge OR decision OR perception OR communication "informed consent"." In Google Scholar, we used the keywords "informed consent" as the exact phrase and "understanding, comprehension, knowledge, decision, perception, communication" with the option with at least one of the words and selected "where my words occur in the title of the article". The search strategy was developed as previously described.[@R20] The searches covered all data entered up to October 2013. In addition, we analysed the reference lists of relevant articles. All studies identified were reviewed independently for eligibility by two of five authors and conflicts were resolved by seeking a consensus with other authors.

A study was eligible for inclusion if it assessed the participant's or the participant's guardian's understanding of informed consent[@R1]^,^[@R2] and at least one of the following components of the informed consent process:[@R8]^,^[@R21] therapeutic misconception (i.e. lack of awareness of the uncertainty of success); ability to name at least one risk; knowing that treatments were being compared; or understanding of: (i) the nature of the study (i.e. awareness of participating in research); (ii) the purpose of the study; (iii) the risks and side-effects; (iv) the direct benefits; (v) placebo; (vi) randomization; (vii) the voluntary nature of participation; (viii) freedom to withdraw from the study at any time; (ix) the availability of alternative treatment if withdrawn from a trial; or (x) confidentiality (i.e. personal information will not be revealed). There was no restriction by language, age (i.e. children or adults) or study design. French and Japanese articles were translated into English by authors with a good command of these languages. We excluded articles on studies that: (i) compared or evaluated methods of informed consent; (ii) used an intervention to improve participants' knowledge of informed consent; (iii) involved animals or included only healthy volunteers (e.g. simulated studies); (iv) involved patients with cognitive deficits; (v) were published as posters, in conference proceedings or as a thesis; or (vi) were not clinical trials. Our study protocol was registered with the international prospective register of systematic reviews (PROSPERO) with the identifier CRD42013005526. The study selection process, which was carried out in accordance with MOOSE guidelines for meta-analyses and systematic reviews of observational studies, is shown in [Fig. 1](#F1){ref-type="fig"}.[@R22]

![Flow diagram for the selection of studies on participants' understanding of informed consent in clinical trials](BLT.14.141390-F1){#F1}

Quality of evaluation
---------------------

The quality of the informed consent evaluation was assessed independently by two authors using seven metrics: (i) the description of participants; (ii) whether or not interviewers were members of the original trial's staff; (iii) the description of the evaluation method (i.e. by questionnaire or interview); (iv) the description of the questionnaire; (v) the selection of participants (i.e. consecutive participants or a random or cross-sectional selection); (vi) the description of exclusion criteria; and (vii) the timing of the evaluations. Quality scores for the studies included are shown in Appendix A (available at: <https://www.researchgate.net/publication/270506278_Online_Only_Supplements_for_Three_decades_of_participants_understanding_of_informed_consent_in_clinical_trials_a_systematic_review_and_meta-analysis>).

Study data
----------

Data were extracted for each study on: (i) the year of publication; (ii) the study language and the country where the study was conducted; (iii) the phase of the study; (iv) the baseline characteristics of the study population, including the source of the population, the number of participants and their age, sex and educational level; (v) the medical specialty of the clinical research, including the seriousness of the disease studied; (vi) the method and timing of the informed consent evaluation; (vii) the type of questions participants had to answer; and (viii) the components of informed consent assessed, including understanding of the nature and purpose of the study, knowing that treatments were being compared, therapeutic misconceptions, participants' ability to name risks, awareness of potential risks and side-effects and understanding of potential benefits, randomization, placebo, the voluntary nature of participation, freedom to withdraw at any time, confidentiality and the availability of alternative treatment.

Statistical analysis and data synthesis
---------------------------------------

If a study investigated more than one population, a data set was created for each population. The proportion of participants who understood the different components of informed consent was pooled across studies using Comprehensive Meta-Analysis software version 2.0 (Biostat, Englewood, United States of America) and was expressed as a percentage with 95% confidence intervals (CIs). The heterogeneity of study findings was evaluated using the *Q* statistic and the *I*^2^ test and was considered significant if the *P*-value was \< 0.10. Since studies gave heterogeneous results for all components, the proportion of participants who understood each component was pooled using a random-effects model that included weighting for each study. In examining the effect of covariates on these proportions, we used a subgroup or meta-regression analysis when eight or more studies assessed a particular covariate. Differences between subgroups and trends were considered significant if the *P*-value of Cochran's *Q* test was \< 0.05.[@R23] To determine if publication bias was present, we used Begg's funnel plot and Egger's regression test: a *P*-value \< 0.10 indicated significant publication bias.[@R24] When publication bias was present, we used Duvall and Tweedie's trim-and-fill method to enhance symmetry by adjusting for studies that appeared to be missing.[@R25]^--^[@R27] The final proportion of participants who understood each component was computed after adjustment for missing studies.

Results
=======

The final analysis included 103 studies: 85 from the database search and 18 from reviewing reference lists.[@R28]^--^[@R130] Ultimately 135 data sets were included because some studies evaluated more than one population (Appendix A). The sample size ranged from 8 to 1789 participants and the response rate to interview questions ranged from 9.3% to 100%. Participants were adults in 95 data sets, parents or guardians in 34, adult and child patients in three, child patients in two and adult patients or parents in one. Overall, 79% (106) of data sets were conducted in middle- or high-income countries -- as classified by the World Bank[@R131] -- and 67% (90) did not report the phase of the clinical trial. The medical specialty was cancer in 33% (44) of data sets, infectious disease in 14% (19), vaccines in 10%, (13) cardiovascular disease in 7% (9), neurology in 6% (8) and other in 31% (42). Moreover, 98% (132) were published in English and only 1% each in Japanese (1) and French (2). Details of the studies and data sets are presented in [Table 1](#T1){ref-type="table"} (available at: <http://www.who.int/bulletin/volumes/93/3/14-141390>).

###### Studies and data sets in the meta-analysis of participants' understanding of informed consent in clinical trials

  Study                       Year   Country (data set, if applicable)                                            Participants                              Subject   Phase of trial                                                         Involved patients with critical conditions   Evaluation of understanding of informed consent                                                                         
  --------------------------- ------ ---------------------------------------------------------------------------- ----------------------------------------- --------- ---------------------------------------------------------------------- -------------------------------------------- ------------------------------------------------- ----- --------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------
  Ellis[@R28]                 2010   USA                                                                          Adult patients                            171       30 (18--50)                                                            Malaria vaccine                              I                                                 No    Questionnaire                                                   After ICP
  Ellis[@R28]                 2010   Mali                                                                         Adult patients                            89        27 (18--50)                                                            Malaria vaccine                              I                                                 No    Questionnaire                                                   After ICP
  Ellis[@R28]                 2010   Mali                                                                         Parents or guardians                      700       ND                                                                     Malaria vaccine                              I                                                 No    Questionnaire                                                   After ICP
  Vallely[@R29]               2010   United Republic of Tanzania                                                  Adult patients                            99        ND                                                                     Infectious disease                           III                                               No    Interviews                                                      4 weeks after ICP
  Hill[@R30]                  2008   Ghana                                                                        Adult and child patients                  1245      15--45 (68% were under 35)                                             Vitamin A supplementation                    ND                                                No    Semi-structured interviews                                      After ICP
  Minnies[@R31]               2008   South Africa                                                                 Parents or guardians                      192       26 (16--44)                                                            Infectious disease                           ND                                                No    Questionnaire with staff assistance                             Within 1 hour of ICP
  Kaewpoonsri[@R32]           2006   Thailand                                                                     Adult patients                            81        32 (18--58)                                                            Infectious disease                           ND                                                No    Semi-structured questionnaire and non-participant observation   At third follow-up visit
  Krosin[@R33]                2006   Mali (rural population)                                                      Adult patients                            78        ND                                                                     Malaria vaccine                              ND                                                No    Questionnaire                                                   Within 48 hours of consent
  Krosin[@R33]                2006   Mali (urban population)                                                      Adult patients                            85        ND                                                                     Malaria vaccine                              ND                                                No    Questionnaire                                                   Within 48 hours of consent
  Moodley[@R34]               2005   South Africa                                                                 Adult patients                            334       68 (60--80)                                                            Influenza vaccine                            ND                                                No    Interviews                                                      4--12 months after the trial
  Pace[@R35]                  2005   Thailand                                                                     Adult patients                            141       \> 18                                                                  Infectious disease                           III                                               No    Interviews                                                      Immediately after ICP
  Pace[@R36]                  2005   Uganda                                                                       Parents or guardians                      347       ND                                                                     Infectious disease                           ND                                                No    Interviews                                                      Immediately after ICP
  Ekouevi[@R37]               2004   Côte d\'Ivoire                                                               Adult patients                            55        26                                                                     Infectious disease                           ND                                                No    Interviews                                                      ND
  Joubert[@R38]               2003   South Africa                                                                 Adult patients                            92        27                                                                     Vitamin A supplementation                    ND                                                No    Interviews                                                      Median of 14 months after ICP
  Lynöe[@R39]                 2001   Bangladesh                                                                   Adult patients                            105       ND                                                                     Iron supplementation                         ND                                                No    Structured questionnaire                                        After ICP
  Lynöe[@R40]                 2004   Sweden                                                                       Adult patients                            44        67.8 (39--82)                                                          Lipid-lowering treatment                     ND                                                No    Questionnaire                                                   1 week after ICP
  Lynöe[@R41]                 1991   Sweden                                                                       Adult and child patients                  43        23 (16--35)                                                            Gynaecology                                  ND                                                No    Questionnaire by mail                                           18 months after the trial
  Lynöe[@R42]                 2004   Sweden                                                                       ND                                        40        ND                                                                     Oncology                                     ND                                                No    Questionnaire                                                   ND
  Lynöe[@R43]                 2001   Sweden                                                                       Adult patients                            26        33 (21--50)                                                            Auricular acupuncture                        ND                                                No    Questionnaire                                                   4 weeks after ICP
  Lynöe[@R43]                 2001   Sweden                                                                       Adult patients                            16        38 (26--45)                                                            Auricular acupuncture                        ND                                                No    Questionnaire                                                   4 weeks after ICP
  Leach[@R44]                 1999   Gambia (rural population)                                                    Parents or guardians                      73        ND                                                                     *Haemophilus influenza* type B vaccine       ND                                                No    Interviews                                                      Within 1 week of ICP
  Leach[@R44]                 1999   Gambia (urban population)                                                    Parents or guardians                      64        ND                                                                     *Haemophilus influenza* type B vaccine       ND                                                No    Interviews                                                      Within 1 week of ICP
  Pitisuttithum[@R45]         1997   Thailand                                                                     Adult patients                            33        55.3 (43--69)                                                          HIV vaccine                                  I, II                                             No    Questionnaire                                                   Prior to ICP
  Bergenmar[@R46]             2008   Sweden                                                                       Adult patients                            282       60 (32--82)                                                            Oncology                                     II, III                                           No    Questionnaire                                                   75% within 3 days of ICP, 99% within 2 weeks
  Knifed[@R47]                2008   Canada                                                                       Adult patients                            21        52 (26--65)                                                            Neuro-oncology                               I, II, III                                        No    Face-to-face interviews                                         Within 1 month of ICP
  Agrawal[@R48]               2006   USA                                                                          Adult patients                            163       57.7 (IQR: 48--68)                                                     Oncology                                     I                                                 No    Structured interview                                            Immediately after ICP
  Franck[@R49]                2007   United Kingdom                                                               Parents or guardians                      109       ND                                                                     25 paediatric trials                         ND                                                Yes   Questionnaire                                                   Immediately after ICP
  Gammelgaard[@R50]           2004   Denmark (patients participating in trial)                                    Adult patients                            103       60                                                                     Acute myocardial infarction                  ND                                                Yes   Questionnaire                                                   ND
  Gammelgaard[@R50]           2004   Denmark (patients declining participation)                                   Adult patients                            78        61                                                                     Acute myocardial infarction                  ND                                                Yes   Questionnaire                                                   ND
  Kodish[@R51]                2004   USA (participants with nurse present at ICP)                                 Parents or guardians                      65        35 (18--51)                                                            Paediatric oncology                          ND                                                No    Interview                                                       Within 48 hours of ICP
  Kodish[@R51]                2004   USA (participants with nurse not present at ICP)                             Parents or guardians                      72        35 (18--51)                                                            Paediatric oncology                          ND                                                No    Interview                                                       Within 48 hours of ICP
  Criscione[@R52]             2003   USA                                                                          Adult patients                            30        44.9 ± 9.8                                                             Rheumatology                                 ND                                                No    Questionnaire                                                   7--28 days after ICP
  Kupst[@R53]                 2003   USA                                                                          Parents or guardians                      20        ND                                                                     Paediatric oncology                          ND                                                No    Structured interview                                            1 month after ICP
  Pope[@R54]                  2003   Canada                                                                       Adult patients                            190       63 (22--84)                                                            Cardiology, ophthalmology and rheumatology   III                                               No    Questionnaire                                                   2 months to 5 years after ICP
  Schats[@R55]                2003   Netherlands (patient consented, patients' understanding of ICP assessed)     Adult patients                            37        ND                                                                     Neurology                                    ND                                                Yes   Structured interview                                            7--31 months after ICP
  Schats[@R55]                2003   Netherlands (patient consented, relatives' understanding of ICP assessed)    Adult patients                            30        ND                                                                     Neurology                                    ND                                                Yes   Structured interview                                            7--31 months after ICP
  Schats[@R55]                2003   Netherlands (relative consented, patients' understanding of ICP assessed)    Adult patients                            17        ND                                                                     Neurology                                    ND                                                Yes   Structured interview                                            7--31 months after ICP
  Schats[@R55]                2003   Netherlands (relative consented, relatives' understanding of ICP assessed)   Adult patients                            17        ND                                                                     Neurology                                    ND                                                Yes   Structured interview                                            7--31 months after ICP
  Simon[@R56]                 2003   USA (ethnic majority)                                                        Parents or guardians                      60        36 (19--51)                                                            Paediatric oncology                          III                                               No    Interview                                                       48 hours after ICP
  Simon[@R56]                 2003   USA (non-English-speaking ethnic minority)                                   Parents or guardians                      21        34 (21--46)                                                            Paediatric oncology                          III                                               No    Interview                                                       48 hours after ICP
  Simon[@R56]                 2003   USA (English-speaking ethnic minority)                                       Parents or guardians                      27        33 (18--45)                                                            Paediatric oncology                          III                                               No    Interview                                                       48 hours after ICP
  Joffe[@R57]                 2001   USA                                                                          Adult patients                            207       55 (57% were aged 45--64)                                              Oncology                                     I, II, III                                        No    Questionnaire by mail                                           3--14 days after ICP
  Daugherty[@R58]             1995   USA                                                                          Adult patients                            27        58 (32--80)                                                            Oncology                                     I                                                 No    Structured interview                                            Before receiving investigational treatment
  Daugherty[@R59]             2000   USA                                                                          Adult patients                            144       59 (26--82)                                                            Oncology                                     I                                                 No    Structured interview                                            Before receiving investigational treatment
  Hietanen[@R60]              2000   Finland                                                                      Adult patients                            261       65 (48--87)                                                            Oncology                                     ND                                                No    Questionnaire by mail                                           5--17 months after ICP
  Montgomery[@R61]            1998   United Kingdom                                                               Adult patients                            158       ND                                                                     Anaesthesia                                  ND                                                ND    Questionnaire by mail                                           6--24 months after ICP
  van Stuijvenberg[@R62]      1998   Netherlands                                                                  Parents or guardians                      181       34                                                                     Paediatrics                                  ND                                                No    Questionnaire                                                   1--3 years after ICP
  Harrison[@R63]              1995   USA (injection-drug users)                                                   Adult patients                            71        37 (18--56)                                                            HIV vaccine                                  II                                                No    Questionnaire                                                   Before ICP signature
  Harrison[@R63]              1995   USA (injection-drug users and other high-risk individuals)                   Adult patients                            71        37 (18--56)                                                            HIV vaccine                                  II                                                No    Questionnaire                                                   Before ICP signature
  Harth[@R64]                 1995   Australia                                                                    Parents or guardians                      62        31                                                                     Asthma                                       ND                                                No    Interview by telephone                                          6--9 months after entering trial
  Estey[@R65]                 1994   Canada                                                                       Adult patients                            29        58 (43--70)                                                            Drug trial                                   ND                                                No    Interview                                                       1--6 weeks after ICP
  Howard[@R66]                1981   USA                                                                          Adult patients                            64        55 (30--69)                                                            Acute myocardial infarction                  ND                                                Yes   Interview                                                       2 weeks to 15 months after ICP
  Griffin[@R67]               2006   USA                                                                          Adult patients                            1789      65 (53% were aged 60--69)                                              Cholesterol treatment                        ND                                                No    Interview                                                       5.1 years after trial
  Guarino[@R68]               2006   USA                                                                          Adult patients                            1086      40.7 (27--72)                                                          Gulf War veterans' illnesses                 ND                                                No    Questionnaire                                                   ND
  Barrett[@R69]               2005   USA                                                                          Adult patients                            8         11.9 (39--76)                                                          Oncology                                     II, III                                           No    Questionnaire                                                   ND
  Sugarman[@R70]              2005   USA                                                                          Adult patients                            627       67 ± 7.2                                                               Several trials on different diseases         ND                                                No    Interview by telephone                                          Right after ICP
  Simon[@R71]                 2004   USA                                                                          Adult patients                            79        51.9 ± 11.2                                                            Oncology                                     III                                               No    Semi-structured interview                                       ND
  Simon[@R71]                 2004   USA                                                                          Adult patients                            140       35.4 ± 7.6                                                             Oncology                                     III                                               No    Semi-structured interview                                       ND
  Pentz[@R72]                 2002   USA                                                                          Adult patients                            100       56 (25--79)                                                            Oncology                                     I                                                 No    Structured interview in person or by phone or mail              ND
  Cohen[@R73]                 2001   USA                                                                          Adult patients                            46        54.9 ± 8.9                                                             Oncology                                     I                                                 No    Questionnaire                                                   Before treatment
  Fortney[@R74]               1999   USA                                                                          Adult patients                            15        ND                                                                     Gynaecology                                  ND                                                No    Structured interview                                            9--39 days after ICP
  Fortney[@R74]               1999   Africa                                                                       Adult patients                            17        ND                                                                     Gynaecology                                  ND                                                No    Structured interview                                            26--250 days after ICP
  Fortney[@R74]               1999   Latin America group I                                                        Adult patients                            19        ND                                                                     Gynaecology                                  ND                                                No    Structured interview                                            26--250 days after ICP
  Fortney[@R74]               1999   Latin America group II                                                       Adult patients                            19        ND                                                                     Gynaecology                                  ND                                                No    Structured interview                                            26--250 days after ICP
  Hutchison[@R75]             1998   United Kingdom                                                               Adult patients                            28        55.4 ± 8.8                                                             Oncology                                     I                                                 No    Structured interview                                            2--4 weeks after ICP
  Négrier[@R76]               1995   France                                                                       Adult patients                            24        56                                                                     Oncology                                     II                                                No    Written questionnaire                                           Immediately after ICP
  Tankanow[@R77]              1992   USA                                                                          Adult patients                            98        44 (18--76)                                                            Drug trials                                  ND                                                ND    Interview based on a questionnaire                              72 hours after ICP
  Rodenhuis[@R78]             1984   Netherlands                                                                  Adult patients                            10        56 (20--72)                                                            Oncology                                     I                                                 No    Structured interview                                            1--6 months after ICP
  Penman[@R79]                1984   USA                                                                          Adult patients                            144       55 (18--65)                                                            Oncology                                     II, III                                           No    Structured interview                                            1--3 weeks after ICP
  Goodman[@R80]               1984   United Kingdom (first study)                                                 Adult patients                            14        66 (50--81)                                                            Anaesthesia                                  ND                                                Yes   Questionnaire                                                   Postoperative phase of the study
  Goodman[@R80]               1984   United Kingdom (second study)                                                Adult patients                            18        ND                                                                     Anaesthesia                                  ND                                                Yes   Questionnaire                                                   Before discharge from hospital
  Riecken[@R81]               1982   USA                                                                          Adult patients                            156       ND                                                                     50 clinical trials                           ND                                                ND    Interview                                                       \< 10 weeks after ICP
  Bergler[@R82]               1980   USA                                                                          Adult patients                            39        55                                                                     Anti-hypertensive treatment                  ND                                                No    Structured interview                                            Immediately after ICP
  Ritsuko[@R83]               2006   Japan                                                                        Adult patients                            279       65                                                                     Clinical trials                              II, III                                           ND    Questionnaire                                                   1 month to 2 years after ICP
  PENTA[@R84]                 1999   Several countries                                                            Parents or guardians                      84        ND                                                                     Drug trial                                   ND                                                No    Questionnaire                                                   Before unblinding the individual child's therapy
  Ballard[@R85]               2004   USA (mothers)                                                                Parents or guardians                      35        26.3 (16--43)                                                          Paediatrics                                  ND                                                No    Questionnaire                                                   3--28 months after ICP
  Ballard[@R85]               2004   USA (fathers)                                                                Parents or guardians                      21        26.3 (16--43)                                                          Paediatrics                                  ND                                                No    Questionnaire                                                   3--28 months after ICP
  Ballard[@R85]               2004   USA (mothers and fathers)                                                    Parents or guardians                      8         26.3 (16--43)                                                          Paediatrics                                  ND                                                No    Questionnaire                                                   3--28 months after ICP
  Bertoli[@R86]               2007   Argentina                                                                    Adult patients                            105       56.3 ± 11.8                                                            Rheumatology                                 III, IV                                           No    Questionnaire                                                   ND
  Burgess[@R87]               2003   Canada (prospective study)                                                   Parents or guardians                      29        30 (21--41) for mothers and 33.4 for fathers                           Neonatology                                  ND                                                Yes   Questionnaire                                                   Prospective study
  Burgess[@R87]               2003   Canada (retrospective evaluation of ICP)                                     Parents or guardians                      44        29.5 (14--40) for mothers and 33.4 for fathers                         Neonatology                                  ND                                                Yes   Questionnaire                                                   \> 1 year after ICP
  Chaisson[@R88]              2011   Botswana (English speakers)                                                  Adult patients                            969       33                                                                     Infectious disease                           ND                                                No    Questionnaire                                                   Within 30 days of ICP
  Chaisson[@R88]              2011   Botswana (Setswana speakers)                                                 Adult patients                            969       33                                                                     Infectious disease                           ND                                                No    Questionnaire                                                   Within 30 days of ICP
  Chappuy[@R89]               2010   France                                                                       Parents or guardians                      43        ND                                                                     Paediatric oncology                          III                                               No    Semi-structured interview                                       After ICP
  Chappuy[@R90]               2013   France                                                                       Parents or guardians                      40        ND                                                                     Oncology                                     III                                               No    Semi-structured interview                                       After study inclusion
  Chappuy[@R91]               2006   France                                                                       Parents or guardians                      68        ND                                                                     HIV infection or oncology                    I, II, III, IV                                    No    Semi-structured interview                                       21 days to 2 years after ICP
  Chappuy[@R92]               2008   France                                                                       Child patients                            29        13.6 ± 2.8                                                             HIV infection or oncology                    I, II, III, IV                                    No    Semi-structured interview                                       After diagnosis
  Chenaud[@R93]               2006   Switzerland                                                                  Adult patients                            44        54 ± 22                                                                Surgical intensive care unit                 ND                                                Yes   Interview                                                       Mean of 10 days (standard deviation: 2) after ICP
  Chu[@R94]                   2012   Republic of Korea                                                            Adult patients                            140       47.2 ± 14                                                              Several diseases                             I, II, III, IV                                    No    Self-administered questionnaire                                 ND
  Constantinou[@R95]          2012   Australia (patients participating in trial)                                  Adult patients                            20        72.2 ± 10.3                                                            Ophthalmology                                ND                                                No    Interview                                                       ND
  Constantinou[@R95]          2012   Australia (patients declining participation)                                 Adult patients                            20        73.1 ± 6.8                                                             Ophthalmology                                ND                                                No    Interview                                                       ND
  Cousino[@R96]               2012   USA (ethnic majority)                                                        Parents or guardians                      60        42 (23--66)                                                            Paediatric oncology                          I                                                 No    Interview                                                       ND
  Cousino[@R96]               2012   USA (ethnic minority)                                                        Parents or guardians                      60        42 (23--66)                                                            Paediatric oncology                          I                                                 No    Interview                                                       ND
  Durand-Zaleski[@R97]        2008   France                                                                       Adult patients and parents or guardians   279       49.5 (39--58) for patients and 40 (35--45) for parents and guardians   ND                                           ND                                                No    Structured interview                                            ND
  Eiser[@R98]                 2005   United Kingdom                                                               Parents or guardians                      50        ND                                                                     Oncology                                     ND                                                No    Semi-structured interview                                       3--5 months after diagnosis
  Featherstone[@R99]          1998   United Kingdom                                                               Adult patients                            20        ND                                                                     Urinary retention treatment                  ND                                                No    Semi-structured interview                                       Seven patients within 3 months and five within 5 months of randomization; eight patients after receiving treatment
  Hazen[@R100]                2007   USA (ethnic majority)                                                        Parents or guardians                      79        ND                                                                     Paediatric oncology                          ND                                                No    Interview                                                       Within 48 hours of ICP
  Hazen[@R100]                2007   USA (ethnic minority)                                                        Parents or guardians                      61        ND                                                                     Paediatric oncology                          ND                                                No    Interview                                                       Within 48 hours of ICP
  Hereu[@R101]                2010   Spain (urgent cases)                                                         Adult patients                            24        52 (22--88)                                                            40 therapeutic trials                        II, III, IV                                       Yes   Structured interview                                            Within 3 months of ICP
  Hereu[@R101]                2010   Spain (non-urgent cases)                                                     Adult patients                            115       52 (22--88)                                                            40 therapeutic trials                        II, III, IV                                       No    Structured interview                                            Within 3 months of ICP
  Hofmeijer[@R102]            2007   Netherlands (extremely urgent treatment)                                     Adult patients                            28        48 ± 8                                                                 Neurology                                    ND                                                Yes   Interview                                                       Median of 13 days (range: 10--16) after ICP
  Hofmeijer[@R102]            2007   Netherlands (less urgent treatment)                                          Adult patients                            30        69 ± 13                                                                Neurology                                    ND                                                Yes   Interview                                                       Median of 13 days (range: 10--16) after ICP
  Itoh[@R103]                 1997   Japan                                                                        Adult patients                            32        58 (30--68)                                                            Oncology                                     I                                                 No    Questionnaire                                                   After ICP and before drug treatment
  Jenkins[@R104]              2000   United Kingdom (patients participating in trial)                             Adult patients                            147       55 (all \> 25)                                                         Oncology                                     ND                                                No    Postal questionnaire                                            ND
  Jenkins[@R104]              2000   United Kingdom (patients declining participation in trial)                   Adult patients                            51        55 (all \> 25)                                                         Oncology                                     ND                                                No    Postal questionnaire                                            ND
  Kass[@R105]                 2005   Two African and one Caribbean country                                        Adult patients                            26        Two thirds were 20--30 and one third were 31--40                       Infectious disease                           ND                                                No    Semi-structured interview                                       ND
  Kenyon[@R106]               2006   United Kingdom                                                               Adult patients                            20        ND                                                                     Gynaecology                                  ND                                                Yes   Interview                                                       ND
  Kiguba[@R107]               2012   Uganda                                                                       Adult patients                            235       38.2 ± 7.5                                                             Infectious disease                           ND                                                No    Semi-structured interview                                       After initial or repeat ICP
  Lidz[@R108]                 2004   USA                                                                          Adult patients                            155       55 (all \> 18)                                                         40 trials on several diseases                I, II, III, IV                                    No    Semi-structured interview                                       ND
  Leroy[@R109]                2011   France                                                                       Adult patients                            75        54.7 (28--82)                                                          Oncology                                     II, III                                           No    Self-assessment questionnaire                                   ND
  Levi[@R110]                 2000   USA                                                                          Parents or guardians                      22        ND                                                                     Paediatric oncology                          ND                                                No    Semi-structured interview                                       ND
  Manafa[@R111]               2007   Nigeria                                                                      Adult patients                            88        39.2 (26--62)                                                          Infectious disease                           ND                                                No    Questionnaire                                                   2 months after enrolment in trial
  McNally[@R112]              2001   United Kingdom                                                               Parents or guardians                      29        32                                                                     Infectious disease                           ND                                                No    Questionnaire                                                   ND
  Mangset[@R113]              2008   Norway                                                                       Adult patients                            11        69.9 ± 8.1                                                             Neurology                                    III                                               Yes   Semi-structured interview                                       ND
  Meneguin[@R114]             2010   Brazil                                                                       Adult patients                            80        58.7 ± 9.3                                                             Cardiology                                   II, III, IV                                       No    Semi-structured interview                                       6 months to 4 years after completion of trial
  Miller[@R115]               2013   USA                                                                          Adult and child patients                  20        17.8 ± 2.4                                                             Paediatric oncology                          I                                                 No    Structured interview                                            Immediately after ICP
  Mills[@R116]                2003   United Kingdom                                                               Adult patients                            21        60 (50--69)                                                            Oncology                                     ND                                                No    Interview                                                       Approximately10 days after ICP
  Nurgat[@R117]               2005   United Kingdom                                                               Adult patients                            38        60 (37--79)                                                            Oncology                                     I, II                                             No    Questionnaire by mail                                           Before or during the first treatment cycle
  Ockene[@R118]               1991   USA                                                                          Adult patients                            28        ND                                                                     Cardiology                                   I                                                 Yes   Interview based on a questionnaire                              After ICP
  Petersen[@R119]             2013   Germany (patients participating in trial)                                    Parents or guardians                      767       ND                                                                     Paediatric oncology                          ND                                                No    Questionnaire by mail                                           ND
  Petersen[@R119]             2013   Germany (patients declining participation)                                   Parents or guardians                      40        ND                                                                     Paediatric oncology                          ND                                                No    Questionnaire by mail                                           ND
  Queiroz da Fonseca[@R120]   1999   Brazil                                                                       Adult patients                            66        18--49                                                                 HIV vaccine                                  ND                                                No    Semi-structured interview                                       ND
  Russell[@R121]              2005   Australia (Aborigines)                                                       Adult patients                            20        95% were \> 16                                                         Pneumococcal vaccine                         ND                                                No    Semi-structured interview                                       Immediately after ICP
  Russell[@R121]              2005   Australia (non-Aborigines)                                                   Adult patients                            20        100% were \> 16                                                        Pneumococcal vaccine                         ND                                                No    Semi-structured interview                                       Immediately after ICP
  Schaeffer[@R122]            1996   USA (phase1)                                                                 Adult patients                            9         53 ± 14.7                                                              Oncology                                     I                                                 No    Questionnaire                                                   24 hours after study inclusion
  Schaeffer[@R122]            1996   USA (phase 2)                                                                Adult patients                            36        56 ± 8.9                                                               Oncology                                     I                                                 No    Questionnaire                                                   24 hours after study inclusion
  Schaeffer[@R122]            1996   USA (phase 3)                                                                Adult patients                            28        33 ± 6.6                                                               Infectious disease                           I                                                 No    Questionnaire                                                   24 hours after study inclusion
  Coulibaly-Traore[@R123]     2003   France                                                                       Adult patients                            57        25 (18--42)                                                            HIV vaccine                                  ND                                                No    Interview                                                       90--180 days after ICP
  Ducrocq[@R124]              2000   France                                                                       Adult patients                            72        62 (29--85)                                                            Neurology                                    ND                                                No    Interview                                                       6--24 hours after study inclusion
  Schutta[@R125]              2000   USA                                                                          Adult patients                            8         57 (42--72)                                                            Oncology                                     I                                                 No    Interview                                                       Immediately after ICP
  Snowdon[@R126]              1997   United Kingdom                                                               Parents or guardians                      71        30.5 (22--44)                                                          Neonatology                                  ND                                                Yes   Semi-structured interview                                       Different times after recruitment to the trial
  Stenson[@R127]              2004   United Kingdom                                                               Parents or guardians                      99        ND                                                                     Neonatology                                  ND                                                Yes   Questionnaire                                                   18 months after the study finished
  Unguru[@R128]               2010   USA                                                                          Child patients                            37        13.6 (7--19)                                                           Paediatric oncology                          I, II, III, IV                                    No    Semi-structured interview                                       ND
  Yoong[@R129]                2011   Australia                                                                    Adult patients                            102       ND                                                                     Oncology                                     I, II, III                                        No    Questionnaire                                                   ND
  Verheggen[@R130]            1996   Netherlands                                                                  Adult patients                            198       ND                                                                     26 trials                                    ND                                                No    Questionnaire                                                   4 weeks after ICP

HIV: human immunodeficiency virus; ICP: informed consent process; IQR: interquartile range; ND: not determined.

^a^ Ages are given as a mean alone, a mean ± standard deviation, a range or a median (range), unless otherwise stated.

Understanding of informed consent
---------------------------------

The number of data sets that covered each component of informed consent is shown in Appendix B (available at: <https://www.researchgate.net/publication/270506278_Online_Only_Supplements_for_Three_decades_of_participants_understanding_of_informed_consent_in_clinical_trials_a_systematic_review_and_meta-analysis>). Understanding of freedom to withdraw at any time was investigated in the largest number of studies (*n* = 79), whereas understanding of placebo was investigated in the smallest number (*n* = 15). Our analysis showed some variation in the proportion of participants who understood different components of informed consent. The highest proportions were 75.8% (95% CI: 70.6--80.3) for freedom to withdraw from the study at any time, 74.7% (95% CI: 68.8--79.8) for the nature of study, 74.7% (95% CI: 67.9--80.5) for the voluntary nature of participation and 74.0% (95% CI: 65.0--81.3) for potential benefits ([Fig. 2](#F2){ref-type="fig"} and Appendix B). Lower proportions were 69.6% (95% CI: 63.5--75.1) for the purpose of the study, 67.0% (95% CI: 57.4--75.4) for potential risks and side-effects, 66.2% (95% CI: 55.3--75.7) for confidentiality, 64.1% (95% CI: 53.7--73.4) for the availability of alternative treatment if withdrawn and 62.9% (95% CI: 45.5--77.5) for knowing that treatments were being compared. In addition, 62.4% (95% CI: 50.1--73.2) had no therapeutic misconceptions. The lowest proportions were 54.9% (95% CI: 43.3--65.0) for naming at least one risk, followed by 53.3% (95% CI: 38.4--67.6) for understanding of placebo and 52.1% (95% CI: 41.3--62.7) for understanding of randomization.

![Participants' understanding of components of informed consent in clinical trials, by meta-analysis^a^](BLT.14.141390-F2){#F2}

Effect of covariates
--------------------

We performed a meta-regression analysis to evaluate the influence of particular covariates on the proportion of participants who understood informed consent ([Table 2](#T2){ref-type="table"}). We found that gender had no effect but that, importantly, significantly fewer patients from low-income countries than from middle- and high countries understood randomization, the voluntary nature of participation and freedom to withdraw at any time. In addition, critically ill patients were significantly less likely to understand the nature or benefits of the study or confidentiality or to be able to name at least one risk. However, older participants were more likely to understand the nature of the study and freedom to withdraw at any time. A lower educational level was associated with a reduced likelihood of understanding the nature of the study, placebo, randomization and freedom to withdraw at any time. Participants in phase-I clinical trials were less likely than participants in phase-II, -III or -IV trials to understand the purpose of the study and were more likely to have therapeutic misconceptions. Participants in phase-I trials were also more likely to understand potential risks and side-effects and freedom to withdraw at any time. Participants assessed using open-ended questions were less likely to understand the purpose of the study ([Fig. 3](#F3){ref-type="fig"}), the voluntary nature of participation or freedom to withdraw at any time or to be able to name at least one risk. Additionally, the later the evaluation of understanding was carried out, the less likely the participant was to understand confidentiality or to be able to name at least one risk. The quality of the evaluation did not influence understanding.

###### Influence^a^ of covariates on participants' understanding of informed consent in clinical trials

  Component of informed consent                        Effect of covariate on understanding of component                                                                                                    
  ---------------------------------------------------- --------------------------------------------------- ----------- ----------- -- ------ ----------- ----------- ----------- -- ----------- ----------- ------
  Nature of the study                                  None                                                None        None           None   Increased   Decreased   Decreased      None        None        None
  Purpose of the study                                 None                                                None        Decreased      None   None        None        None           None        Decreased   None
  No therapeutic misconception^c^                      None                                                ND^d^       Decreased      None   None        ND          None           None        None        None
  Ability to name at least one risk                    None                                                None        None           None   None        Decreased   None           Decreased   Decreased   None
  Risks and side-effects                               None                                                None        Increased      None   None        None        None           None        None        None
  Benefits of the study                                None                                                None        None           None   None        Decreased   None           None        None        None
  Placebo                                              None                                                None        ND             ND     None        ND          Decreased      None        ND          None
  Knowing that treatments were being compared          None                                                ND          ND             None   None        ND          None           None        ND          None
  Randomization                                        None                                                Decreased   ND             None   None        None        Decreased      None        None        None
  Voluntary nature of participation                    None                                                Decreased   ND             None   None        None        None           None        Decreased   None
  Freedom to withdraw at any time                      None                                                Decreased   Increased      None   Increased   None        Decreased      None        Decreased   None
  Availability of alternative treatment if withdrawn   None                                                None        None           None   None        ND          None           None        None        None
  Confidentiality                                      None                                                None        ND             ND     None        Decreased   None           Decreased   ND          None

ND: not determined.

^a^ The influence of the covariate on participants' understanding of the component of informed consent was evaluated by meta-regression analysis.

^b^ Continuous variable.

^c^ No lack of awareness of the uncertainty of success.

^d^ The effect was not determined because there were fewer than five studies per subgroup or fewer than 10 for the regression analysis.

![Effect of using an open-ended question^a^ on participants' understanding of the purpose of a clinical study^b^](BLT.14.141390-F3){#F3}

Our data also provided us with the opportunity to analyse how study participants' understanding of informed consent had changed over 30 years. Surprisingly, there was no significant change in understanding of any component ([Fig. 4](#F4){ref-type="fig"}, [Fig. 5](#F5){ref-type="fig"} and [Fig. 6](#F6){ref-type="fig"}). In particular, we were interested in the past 20 years, after the World Health Organization introduced guidelines for good clinical practice in trials.[@R132] After removing four early studies, we again found no significant change in understanding of any component, including the freedom to withdraw ([Fig. 7](#F7){ref-type="fig"}). Furthermore, there was no significant change in understanding of any component over the past 13 years in all studies combined or in subgroups of participants, including those assessed using open-ended questions, those assessed using closed-ended questions and those in middle- and high-income countries assessed using closed-ended questions (Appendices C, D, E and F, respectively, available at: <https://www.researchgate.net/publication/270506278_Online_Only_Supplements_for_Three_decades_of_participants_understanding_of_informed_consent_in_clinical_trials_a_systematic_review_and_meta-analysis>).

![Participants' understanding of the potential risks and side-effects of participating in a clinical study](BLT.14.141390-F4){#F4}

![Participants' understanding of placebo in clinical studies](BLT.14.141390-F5){#F5}

![Participants' understanding of their freedom to withdraw from a study at any time](BLT.14.141390-F6){#F6}

![Participants' understanding of their freedom to withdraw from a study at any time, after introduction of WHO guidelines for good clinical practice in trials[@R132]](BLT.14.141390-F7){#F7}

Discussion
==========

Obtaining informed consent from participants in clinical research is essential because it promotes their welfare and ensures their rights.[@R9]^,^[@R133] However, participants must have a good understanding of what informed consent entails. Our meta-analysis indicates that around 75% of individuals understood the nature of the study, their right to refuse to participate, their right to withdraw at any time and the direct benefits of participation. This percentage is higher than the figure of around 50% found in a previous systematic review[@R18] probably because we included only clinical trials, excluded studies of patients with cognitive deficits and weighted the meta-analysis to account for heterogeneous data.

Our data also highlight the difficulty participants had in understanding particular components of informed consent, such as randomization and the use of placebo. Moreover, although participants were aware of potential risks and side-effects, they were less likely to be able to name at least one risk and, although they understood the benefits of participating in a study, they were less aware of the uncertainty of these benefits (i.e. had therapeutic misconceptions). These findings were also noted in previous studies.[@R18]^,^[@R19]^,^[@R134]^--^[@R137] They are, perhaps, not surprising since a participant's understanding depends, to a certain degree, on their literacy as well as on the duration of the informed consent process and the explanatory skills of the researchers.[@R138]^--^[@R140]

In addition, the meta-regression was able to identify differences in understanding of informed consent between population groups. Older participants more often than younger participants understood the nature of the study and freedom to withdraw at any time. The reason for this difference requires further study. As noted in a previous systematic review,[@R19] participants from developing countries were less likely than others to understand the voluntary nature of participation and freedom to withdraw at any time. It is possible that patients in these countries dare not refuse to join or dare not withdraw from a study because they fear their doctor's disapproval.[@R141] Participants from developing countries and those with a low level of literacy were less likely to understand randomization.

Phase-I clinical trials are usually conducted in small numbers of participants to test a drug's safety and dose range. Consequently, it was expected that participants in phase-I trials would be less likely than those in more advanced trials to understand the purpose of the study or that the benefits were uncertain. In contrast, participants in phase-I trials were more likely to be aware of potential risks and of their freedom to withdraw at any time.

Compared with the use of open-ended questions to evaluate participants\' understanding, the use of closed-ended questions was associated with higher rates of understanding of the purpose of the study, the voluntary nature of participation and freedom to withdraw and with a greater likelihood of being able to name at least one risk. However, the use of closed-ended questions could have led to understanding being overestimated because respondents had to choose from a limited number of possible answers and did not have to think clearly about the issues.[@R142] Consequently, the use of open-ended questions may have reflected better the true extent of understanding since respondents had to put their understanding into words.[@R143]

Finally, an unexpected finding of our analysis was that understanding of the potential risks and side-effects of trials, of placebo and of freedom to withdraw had not changed over 30 years. This is despite considerable progress in medical research methods over this time[@R144] and many attempts made to improve the quality of informed consent.[@R145] There are four possible explanations: (i) the maximum proportion of participants who understand these concepts has been reached; (ii) the increasing complexity of clinical trials has made the informed consent process longer and more difficult to understand; (iii) not enough effort has been put into enhancing the quality of the informed consent process; and (iv) our analysis did not have the statistical power to detect a significant increase in understanding. In fact, the best way to improve understanding of informed consent is still debated. A recent meta-analysis of interventions for improving understanding found that enhanced consent forms and extended discussions led to significant increases in understanding whereas multimedia approaches did not.[@R146] In other words, simple measures such as well formatted, easily readable consent forms and intensive discussions with participants may be more effective than more complex measures.[@R140]^,^[@R146]^--^[@R148]

Although an understanding of all the components of informed consent we investigated is required for patients to make a decision on study participation, some components were assessed more often than others. We found a good correlation between the likelihood that a participant would understand a specific component of informed consent and the number of studies that investigated understanding of that component (Appendix G). This suggests either that it was simpler to evaluate understanding of some components or that some components were more important.

One limitation of our study is that we were not able to analyse the effect on understanding of informed consent of the presence of a nurse during the informed consent process, of the duration of the process or of participants choosing not to take part in a clinical trial because only a small number of studies investigated these factors. Moreover, only 79 of the 135 data sets gave information on whether the interviewers were investigators in the original clinical trial. Hence, we were not able to analyse the effect of this factor on the results. Another limitation is that we included studies of children because they have the right to decide whether to participate.[@R149]^,^[@R150] However, the number of studies involving children was small and our sensitivity analysis showed that removing these studies did not influence the pooled results. Although we found a high level of heterogeneity across studies for understanding of all components of informed consent and although Cox et al. suggest that, in these circumstances, individual studies should be described rather than combined in a meta-analysis,[@R151] we, like other groups, chose to perform a meta-analysis with a regression analysis and subgroup analysis to gain a better insight into how covariates affect understanding.[@R152]^--^[@R154]

In conclusion, we found that most participants in clinical trials understood fundamental components of informed consent such as the nature and benefits of the study, freedom to withdraw at any time and the voluntary nature of participation. Understanding of other components, such as randomization and placebo, was less satisfactory and has not improved over 30 years. Our findings suggest that investigators could make a greater effort to help research participants achieve a complete understanding of informed consent. This would ensure that participants' decision-making is meaningful and that their interests are protected.
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